Clinical trials: Advanced Rectal Cancers
Colorectal Polyp, Colorectal Cancer
Detection of Endoscopic Resection Scars and Delineation of Recurrence is Trainable
Colorectal cancer is prevented by colonoscopy and polypectomy. Failure to recognize the endoscopic resection scar after Endoscopic Mucosal Resection (EMR) risks unrecognized recurrent or residual adenoma (RRA), which may…
- Trial name
- SCAR (NCT06193356)
- Testing
- Learning tool
- Where
- Belgium
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Metastatic Colorectal Cancer (CRC)
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
This study is a randomized, controlled, open-label, phase II clinical study. This study is designed to evaluate the efficacy and safety of second-line standard treatment sequential TAS-102 and bevacizumab combined with local…
- Trial name
- TASBEL (NCT06856187)
- Testing
- TAS-102+bevacizumab+local treatment, Standard chemotherapy
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Fudan University
Rectal Cancer
Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
The study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have…
- Trial name
- NCT02008656
- Testing
- Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin
- Where
- 26 sites in United States
- Volunteers
- 358 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth…
- Trial name
- NCT00026299
- Testing
- ZD1839, oxaliplatin
- Where
- 12 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Chicago
Colorectal Cancer
Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab.
Italian, multicentre, non comparative trial in patients with advanced Colorectal Cancer(CRC)and KRAS wild-type, defined by molecular evaluation.
- Trial name
- NCT01068132
- Testing
- Cetuximab, FOLFIRI
- Where
- 7 sites in Italy
- Volunteers
- 54 people
- Sponsor
- Regione Lombardia
Locally Advanced Rectal Cancer (LARC)
Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer
This interventional, non-randomized, prospective trial aims to evaluate the role of endoscopic resection following neoadjuvant treatment in patients with locally advanced rectal cancer.
- Trial name
- OPAL (NCT06761287)
- Testing
- Endoscopic resection, Short interval restaging, Total mesorectal excision
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Colorectal Cancer
Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006366
- Testing
- fluorouracil, irinotecan hydrochloride, conventional surgery
- Where
- 235 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Colorectal Cancer
Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients
The study aims to identify the efficacy and safety of capecitabine plus oxaliplatin (XELOX) in patients with local advanced colorectal cancer.
- Trial name
- NCT02415829
- Testing
- capecitabine plus oxaliplatin
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fudan University
Locally Advanced Rectal Carcinoma
Comparison of the Clinical Response of Total Neoadjuvant Treatment of Two Methods of Long-term or Short-term Chemoradiotherapy in Rectal Cancer
Rectal cancer is one of the most prevalent malignancies in the world, and its prevalence is rising. In more advanced cases neoadjuvant therapy is advised before to surgery, and radiotherapy is one of its cornerstones.
- Trial name
- TEHRAN (NCT05920928)
- Testing
- Short course radiotherapy with concurrent capecitabine(825mg/m2), Long course radiotherapy with concurrent capecitabine(825mg/m2)
- Volunteers
- 114 people
- Sponsor
- Tehran University of Medical Sciences
Rectal Neoplasms, Rectal Cancer, Adenocarcinoma
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer
The goal of this randomized controlled clinical trial is to learn if adding fruquintinib to short-course radiotherapy, tislelizumab, and CAPOX can improve neoadjuvant treatment response and is safe for adults with locally…
- Trial name
- TRIP-FAST (NCT07888309)
- Testing
- Short-Course Radiotherapy, Fruquintinib, Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Non-small Cell Lung Cancer, Metastatic Colorectal Cancer
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung…
- Conditions
- Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Kidney Cancer
- Trial name
- NCT04889495
- Testing
- Zirabev
- Sponsor
- Pfizer
Metastatic Colorectal Cancer (CRC), Colorectal Cancer
Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with chemotherapy.
- Trial name
- NCT07286695
- Testing
- Fruquintinib Combined With trifluridine/tipiracil, Bevacizumab combined with trifluridine/tipiracil
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Neoplasms, Lung Neoplasms
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to…
- Conditions
- Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms
- Trial name
- N1 (NCT02900248)
- Testing
- Provider determined
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- CureOne
Non Small Cell Lung Cancer, Bladder Cancer
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body.
- Conditions
- Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06580938
- Testing
- PF-07921585, Sasanlimab
- Where
- 9 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Colorectal Cancer
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
- Trial name
- NCT05948826
- Testing
- TORL-3-600
- Where
- 9 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Advanced Colorectal Cancer
Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency
To assess the efficacy of methotrexate in a genetically selected population of patients with advanced colorectal cancer, who have loss of a particular gene, MSH2.
- Trial name
- MESH (NCT00952016)
- Testing
- Methotrexate
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Cancer of Rectum
Study to Nivolumab Following Preoperative Chemoradiotherapy
This is a phase Ib/II, open-label, single-arm, multicenter study to investigate the safety, efficacy, and proof of concept (POC) of monotherapy with nivolumab, an anti-PD-1 antibody drug, as a sequential therapy following…
- Trial name
- NCT02948348
- Testing
- Nivolumab, Ipilimumab
- Where
- 3 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Takayuki Yoshino
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Advanced Solid Tumors
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagrasib.
- Trial name
- NCT06039384
- Testing
- INCB099280, adagrasib
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 6 people
- Sponsor
- Incyte Corporation
Colorectal Neoplasms, Breast Neoplasms
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Background: Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells.
- Trial name
- NCT02484404
- Testing
- Olaparib, Cediranib, Durvalumab
- Where
- United States
- Volunteers
- 268 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.